Carboplatin
Autosomal Dominant Parkinson Disease 1
Explore 7 assets in Autosomal Dominant Parkinson Disease 1 →Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Shandong New Time Pharmaceutical Co., LTD
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05741021CT.gov A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Autosomal Dominant Parkinson Disease 1
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Carboplatin (this asset) | Shandong New Time Pharmaceutical Co., LTD | P2 | CCC · 53 |
| Ruxoprubart | Shanghai Pulmonary Hospital, Shanghai, China | P2 | CCC |
| Dasatinib | The Affiliated Hospital of Qingdao University | P2 | CCC |
| f520 | Shandong New Time Pharmaceutical Co., LTD | P2 | CCC |
| Tuvonralimab | Anhui Provincial Hospital | P2 | CCC |
| Lenvatinib | The First Affiliated Hospital with Nanjing Medical University | P2 | CCC |
| pd1-til | Ruijin Hospital | P1 | CC |
| pd-1 knockout engineered t cells | Ruijin Hospital | P1 | CC |
Other indications for Carboplatin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Lung Large Cell Carcinoma | — | P4 | A · 80 |
| Primary Peritoneal Carcinoma | — | P3 | BBB · 76 |
| Non-Small Cell Squamous Lung Carcinoma | — | P3 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Carboplatin in Autosomal Dominant Parkinson Disease 1. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/carboplatin-autosomal-dominant-parkinson-disease-1
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →